Mako anchors the orthopedic sub-cohort triangle of DEPLOY's surgical cluster (large-footprint Mako / handheld CORI / mid-size ROSA), the orthopedic-domain expansion beyond the general-laparoscopy systems (da Vinci, Hugo, Ottava, Versius).
✔
It is the multi-procedure leader: cleared across knee, hip, Mako Spine (510(k) K241517, May 2024) and Mako Shoulder (510(k) K242373, November 2024), in 45-plus countries, with CT-based planning and AccuStop haptic boundary control.
Price
No reviewed price is on record. We do not treat unverified analyst estimates as pricing data. There is no consumer price. Mako is enterprise B2B surgical equipment sold to hospitals on per-system contracts, so DEPLOY records zero price points.
Availability
Internal use only
Mako is sold to hospitals, not consumers. From Stryker (NYSE: SYK), it is in 45-plus countries, cleared across knee, hip, Mako Spine (510(k) K241517, May 2024), and Mako Shoulder (510(k) K242373, November 2024).
Real-world status
Stryker's Mako (Mako SmartRobotics) is a surgeon-guided robotic arm for orthopedic joint replacement and the large-footprint, CT-based, multi-procedure archetype of DEPLOY's orthopedic surgical sub-cohort. It pairs CT-based 3D pre-operative planning with intra-operative haptic boundary control (AccuStop physically constrains the saw or burr to the planned resection zone) and real-time optical bone tracking. It is AI-augmented but surgeon-controlled, not autonomous: the surgeon holds and guides the arm and makes every cut, the same assistive class as Intuitive's da Vinci. Cleared procedures span partial and total knee, cementless total knee, total hip and hip revision, Mako Spine (pedicle-screw placement), and Mako Shoulder (reverse shoulder arthroplasty).
⚠
AI-augmented, NOT autonomous: the surgeon holds and guides the arm and makes every cut (the same assistive class as da Vinci). Separately, Stryker frames itself in SEC filings as 'one of four leading global competitors,' not a specific market-share percentage; aggregator share figures are unverified.
⊘
There is no consumer price. Mako is sold to hospitals on per-system contracts, so DEPLOY records zero price points.
No⊘absence. It is enterprise B2B surgical equipment sold to hospitals on per-system contracts; there is no consumer price.
Is the Mako autonomous?
No, it is AI-augmented but surgeon-controlled🟢verified: the surgeon holds and guides the arm and makes every cut. AccuStop haptic boundary control constrains the tool to the plan, but the robot never cuts on its own.
What procedures does the Mako do?
Partial and total knee, total hip and revision, Mako Spine (K241517, May 2024), and Mako Shoulder (K242373, Nov 2024)🟢verified.
Is the Mako the market leader?
Stryker frames itself in SEC filings as one of four leading global competitors🟢verified, not a specific market-share percentage; aggregator share figures are unverified.
How does the Mako compare to CORI and ROSA?
Mako is the large-footprint, CT-based, multi-procedure system🟢verified; CORI is handheld and imageless (knee-robotic), and ROSA is a mid-size cross-domain arm (ortho + neuro).
Pricing and availability are tagged verified or claimed against primary sources. Manufacturer targets are reported as targets, not prices you can pay today.